The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study
Frontiers in Cellular and Infection Microbiology · 06.08.2024 · 14
DOI: 10.3389/fcimb.2024.1419015 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 06.08.2024. Verfasst von Yuzhang Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Severe Fever with Thrombocytopenia Syndrome, Glucocorticoids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Severe fever with thrombocytopenia syndrome (SFTS) is prevalent in East Asia. However, the use of glucocorticoids (GCs) in the treatment of SFTS remains controversial.
Methods
In this retrospective cohort study, we collected the data from patients with SFTS at Wuhan Union Hospital to evaluate the effect of GC therapy. Mortality and secondary infections were compared as outcomes. After searching public databases, we also included articles that examined GC use in patients with SFTS for meta-analysis.
Results
Patients treated with GC had higher fatality rates (21.1% vs. 11.9%, respectively; P =0.006) and a longer length of stay (10.6 ± 5.1 vs. 9.5 ± 4.2, respectively; P =0.033). In cohorts adjusted using propensity score matching and inverse probability of treatment weighting, no significant differences in fatality rates and length of stay were observed. A meta-analysis of 4243 SFTS patient revealed that those treated with GCs had significantly higher mortality (OR=3.46, 95% CI =2.12-5.64, P <0.00001) and secondary infection rate (OR=1.97, 95% CI=1.45-2.67, P <0.0001).
Discussion
GC should be used cautiously when treating SFTS. No significant differences were identified in terms of mortality and secondary infection rates between patients with SFTS treated with or without GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zitieren
APA
Chen, Y., Wang, H., Zhou, F., & Guo, C. (2024). The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1419015
Vancouver
Chen Y, Wang H, Zhou F, Guo C. The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1419015
BibTeX
@article{Chen2024,
author = {Chen, Yuzhang and Wang, Huan and Zhou, Fengqin and Guo, Chunxia},
title = {The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
volume = {14},
doi = {10.3389/fcimb.2024.1419015}
}
EUVIMED